METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Metagenomi, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Metagenomi securities pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9, 2024, and May 1, 2024, both dates inclusive (the “Class Period”). Investors have until November 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The Complaint alleges Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Metagenomi introduced itself to investors during its initial public offering as a “genetic medicines company” having a long-standing business relationship with Moderna, one of the leading Covid-19 vaccine companies and integral to Metagenomi's collaboration with Moderna was the claim that the two companies had entered into a Strategic Collaboration and License Agreement on October 29, 2021, which included multiple four-year research programs and a subsequent licensed product-by-licensed product agreement.
If you purchased or otherwise acquired Metagenomi shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com
Previous Posts:
- ACHC INVESTOR UPDATE: Did Acadia Healthcare Mislead Investors Causing Losses? Contact BFA Law about its Pending Securities Fraud Lawsuit (Nasdaq:ACHC)
- TD INVESTOR UPDATE: Did TD Bank Mislead Investors Causing Losses? Contact BFA Law about the Pending Securities Fraud Lawsuit (NYSE:TD)
- Legal Soft Expands Virtual Talent Pool to Meet Surging Client Demand
Next Posts:
- LifeWallet Announces New Comprehensive Settlements Totaling More Than $5.9 Million, Continued Progress in Recoveries on Owned Claims and Acquiring Rights to Additional Claims, and Initiatives to Eliminate Wasteful Medicare Spending by Launching Beta Testing of Its Clearinghouse Solution, Built in Partnership with Palantir Technologies, Inc.
- Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44
- Mediation and Dispute Resolution for UK In-house Lawyers Training Course (ONLINE EVENT: June 9, 2025/ON-DEMAND)